Rein Therapeutics (RNTX) 10-K2020 FY Annual report

Filed: 24 Mar 21, 4:31pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: aforementioned, Aid, alopecia, ATM, Biden, biometric, bladder, bodyweight, borrower, CAA, carryback, cavity, charitable, checkpoint, chemo, chemoprotection, chemoprotective, CMC, COSELA, covenanted, CTCAE, default, depth, derecognition, derecognized, destruction, distancing, extinguishment, fatal, febrile, FFCR, fight, floor, follicle, forgivable, forthcoming, frontline, fundamentally, futility, GDPR, GTHX, hair, hallmark, hedging, immunochemotherapy, incentivizing, JonesTrading, lessen, Lincoln, loan, lodge, LPC, marginal, metro, migrated, mimicking, monthly, myelosuppression, nationwide, NSCLC, offshore, onsite, overturning, Park, Paycheck, pemetrexed, penalty, pillar, Pleasant, plinabulin, poster, PPP, precautionary, preceding, prevailing, prolong, redirect, reevaluate, Regular, remote, repatriated, rescinded, resell, robust, Satter, shield, skin, SMTP, social, supervisory, sweeping, Symposium, taxation, telemedicine, temporarily, Terminology, thereunder, top, topline, tract, traffic, unforgiven, unpleasant, usage, vision, volunteer, whatsoever, whichever, window, worsen

Removed: abnormal, absence, additive, Afinitor, arrive, assay, Cambridge, Canaccord, capecitabine, Certified, circulating, cleft, Click, correlation, dabrafenib, deactivating, dealing, decoy, deep, demethylating, depreciated, destroy, detach, dexamethasone, discontinued, dissolution, encouraging, enterprise, exceeded, expression, Fenner, field, fourth, Gazyva, Genuity, hematologic, highest, Hoffman, hybrid, ideal, inactivation, incremental, infusion, inherited, input, intention, invade, investigated, invoicing, killing, kinase, La, localized, Lonsurf, Lynch, MAPK, maturing, median, mediated, melanoma, Merrill, metastasized, mTOR, nanomolar, neutrality, noted, nullifying, obinutuzumab, objective, OPM, overexpressing, overexpression, partially, persistence, Pfizer, pharmacodynamic, Pierce, PK, pocket, power, preference, preservation, profiling, prohibited, PWERM, regime, restore, restrain, retained, Rituxan, rituximab, selectivity, shrink, shrinkage, similarity, Smith, split, stay, structural, subjective, suppression, suppressor, survive, Tafinlar, targeting, Task, undruggable, vemurafenib, vendor, vigilance, worse, Xeloda, Zelboraf

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

RNTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Aileron Therapeutics, Inc. (the “Company”) for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: March 24, 2021		/s/ Richard J. Wanstall
		Richard J. Wanstall
		Principal Financial Officer and Chief Financial Officer